Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $20.32 and last traded at $20.37, with a volume of 83945 shares traded. The stock had previously closed at $20.72.
Wall Street Analyst Weigh In
Separately, Piper Sandler decreased their price objective on Fulgent Genetics from $28.00 to $25.00 and set a "neutral" rating for the company in a report on Wednesday, March 6th.
Get Our Latest Analysis on Fulgent Genetics
Fulgent Genetics Price Performance
The firm has a 50-day moving average of $22.97 and a 200 day moving average of $25.47. The stock has a market capitalization of $600.69 million, a price-to-earnings ratio of -3.62 and a beta of 1.43.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.61. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. The firm had revenue of $70.51 million during the quarter, compared to analysts' expectations of $67.14 million. On average, equities analysts forecast that Fulgent Genetics, Inc. will post -2.04 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Covington Capital Management lifted its position in shares of Fulgent Genetics by 133.3% in the third quarter. Covington Capital Management now owns 700 shares of the company's stock valued at $27,000 after buying an additional 400 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Fulgent Genetics by 416.8% in the first quarter. Geneos Wealth Management Inc. now owns 491 shares of the company's stock valued at $30,000 after buying an additional 396 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Fulgent Genetics in the third quarter valued at approximately $34,000. Covestor Ltd lifted its position in shares of Fulgent Genetics by 48.0% in the third quarter. Covestor Ltd now owns 1,508 shares of the company's stock valued at $40,000 after buying an additional 489 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Fulgent Genetics in the fourth quarter valued at approximately $46,000. 48.06% of the stock is owned by institutional investors and hedge funds.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
See Also
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
